Identification of Patient Important Outcomes in Lung Transplantation
NCT ID: NCT06066229
Last Updated: 2023-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2023-10-10
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patient-Important Outcomes (PIO), have emerged across various medical fields, aiming to prioritize the patient's perspective in medical research. This approach seeks to align clinical outcomes with those important to patients, such as pain, mobility, autonomy, and quality of life.
The focus on patient-centered research is crucial not only in medical care but also in clinical research. While several medical fields have embraced this approach, including diabetology, rheumatology, urology, and more, the field of lung transplantation has yet to fully explore the importance of PIO.
LT addresses diverse underlying conditions (e.g., cystic fibrosis, pulmonary fibrosis, emphysema, pulmonary hypertension), impacting potentially different patient populations. However, the transplantation process standardizes certain aspects, such as follow-up obligations, treatments, side effects, and complications, which can affect patient quality of life.
A systematic literature review of LT studies published in 2019 found that only 11 out of 51 studies evaluated PIOs beyond mortality. This highlights the need to assess interventions in this field based on criteria important to patients.
Besides the impact on the patient, the influence on their close family members and caregivers is significant. The transition from severe respiratory disease to near-normal respiratory function can lead to a reevaluation of the caregiver's role and responsibilities.
Currently, researchers and clinicians in transplantation focus more on Patient-Reported Outcomes (PRO) than on outcomes important to patients. To bridge this gap, this study aims to identify PIOs from the perspectives of clinicians, transplant recipients, and their families.
The Delphi method is chosen to gather anonymous expert opinions and reach a consensus on defining PIOs in the context of lung transplantation.
Ultimately, this research aims to create a "core outcome set" necessary for LT research, incorporating dimensions beyond mortality, which is the traditional focus in assessing transplant outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trajectories of FEV1 After Lung Transplantation
NCT05934617
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
NCT06399302
Patient Reported Outcomes in Living Donor Lung Transplantation
NCT00905697
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
NCT04837339
Prediction of Pulmonary Graft Dysfunction After Double-lung Transplantation (PGD3-AI Study)
NCT04643665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This methodology has been used, among others, to identify important evaluation domains for survivors of acute respiratory distress syndrome and their families (Dinglas, Thorax 2018).
Formation of four panels:
* Patients followed in one of the two participating centers (Bichat Hospital, Paris; Foch Hospital, Suresnes).
* Relatives (spouses, partners, or, if not available, first-degree relatives) of patients in one of the participating centers.
* Clinician doctors and researchers from LT centers, belonging to the lung transplantation group of the French Language Pneumology Society or the francophone network of investigators.
* Paramedical caregivers (nurses, advanced practice nurses, transplantation coordination nurses, psychologists, physiotherapists, etc.) working in one of the French or identified French-speaking centers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung transplant patients
Adult lung transplant patients followed at Hôpital Bichat (Paris) or Hôpital Foch (Suresnes)
Questionnaire- Delphi method
Identify important evaluation criteria for lung transplant patients by rating each criterion
Relatives of lung transplant patients
Close relatives of lung transplant patients (spouse; partner; first-degree parent) followed at Bichat Hospital (Paris) or Foch Hospital (Suresnes).
Questionnaire- Delphi method
Identify important evaluation criteria for lung transplant patients by rating each criterion
Physicians from lung transplant
Physicians from lung transplant centers in France, or French-speaking experts identified in the professional network of investigators
Questionnaire- Delphi method
Identify important evaluation criteria for lung transplant patients by rating each criterion
Paramedical staff
Nurses, psychologists, physiotherapists, etc.) from the same French center or French-speaking centers whose primary focus is on caring for lung transplant patients
Questionnaire- Delphi method
Identify important evaluation criteria for lung transplant patients by rating each criterion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire- Delphi method
Identify important evaluation criteria for lung transplant patients by rating each criterion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Close relatives of lung transplant patients (spouse; partner; first-degree parent) followed at Bichat Hospital (Paris) or Foch Hospital (Suresnes).
* Physicians from lung transplant centers in France, or French-speaking experts identified in the professional network of investigators.
* Paramedical staff (state certified nurses, psychologists, physiotherapists, etc.) from the same French center or French-speaking centers whose primary focus is on caring for lung transplant patients.
Exclusion Criteria
* Minor patients or minor close relatives.
* Patients or close relatives of recently transplanted patients (immediate post-transplant hospitalization).
* Patients or close relatives of patients who have undergone a combined transplant (liver-lung, heart-lung, kidney-lung).
* Non-comprehension of the French language.
* Inability to use computer tools.
* Refusal to participate.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
WEISENBURGER Gaëlle, MD
Role: PRINCIPAL_INVESTIGATOR
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS-Hôpital Bichat
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP 220838
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.